Clinical trials: Dexamethasone Administration
AL Amyloidosis
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
This phase 2 study ain to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy.
- Trial name
- IsAMYP (NCT05066607)
- Testing
- Isatuximab
- Where
- 15 sites in France
- Volunteers
- 46 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
- Trial name
- NCT01998971
- Testing
- Daratumumab, Velcade, Pomalidomide
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Multiple Myeloma
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
A multicenter, double arms, prospective randomized controlled phase 4 study. Approximately 50 previously untreated subjects with multiple myeloma will be enrolled.
- Trial name
- NCT01868828
- Testing
- PAD, VCD, ASCT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Nasal and Nasal-type NK/T-cell Lymphoma
Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.
- Trial name
- CTTNKTL-Ⅲ/Ⅳ (NCT01501149)
- Testing
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang
Inflammation, Perioperative Morbidity
The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))
Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery.
- Trial name
- NCT00995501
- Testing
- Dexamethasone Sodium Sulfate, Insulin, anesthesia management
- Where
- United States
- Volunteers
- 381 people
- Sponsor
- d sessler
Prostate Cancer
Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.
- Trial name
- INV342 (NCT00427999)
- Testing
- imatinib mesylate, Treosulfane, etoricoxib
- Where
- 10 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT04883242
- Testing
- Carfilzomib, Dexamethasone, Isatuximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Multiple Myeloma
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively…
- Trial name
- MonumenTAL-3 (NCT05455320)
- Testing
- Talquetamab, Daratumumab, Pomalidomide
- Where
- 216 sites in United States, Belgium and 16 more
- Volunteers
- 864 people
- Sponsor
- Janssen Research & Development, LLC
Acute Respiratory Distress Syndrome
Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome
BACKGROUND: Currently, there is no proven pharmacologic treatment for patients with the acute respiratory distress syndrome (ARDS).
- Trial name
- DEXA-ARDS (NCT01731795)
- Testing
- Dexamethasone
- Where
- 2 sites in Spain
- Volunteers
- 277 people
- Sponsor
- Hospital Universitario de Gran Canaria Doctor Negrín
Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, romiplostim and high-dose dexamethasone.
- Trial name
- NCT04588194
- Testing
- Romiplostim, Rituximab, Dexamethasone
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- David Gomez Almaguer
Multiple Myeloma
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan…
- Trial name
- NCT00205751
- Testing
- Thalidomide/Dexamethasone vs Melphalan/Prednisone
- Where
- Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Forum Against Cancer
Rib Fractures, Acute Pain
Comparison of Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Erector Spinae Plane Block for Acute Pain Management in Patients With Traumatic Rib Fractures
Traumatic rib fractures cause severe chest wall pain that can impair normal breathing, coughing, and lung function. While systemic opioids are commonly used to treat traumatic pain, their side effects, such as sedation and…
- Conditions
- Rib Fractures, Acute Pain, Thoracic Trauma
- Trial name
- NCT07827157
- Testing
- Dexmedetomidine with Bupivacaine in ESPB, Dexamethasone with Bupivacaine in ESPB
- Volunteers
- 100 people
- Sponsor
- Assiut University
Plasma Cell Myeloma Refractory
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult…
- Trial name
- SubQSA (NCT06356571)
- Testing
- Isatuximab SC-OBDS, Montelukast, Dexamethasone
- Where
- 34 sites in United States
- Volunteers
- 64 people
- Sponsor
- Sanofi
Multiple Myeloma
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Bortezomib-based triple-drug combination has greatly improved the response rate of multiple myeloma patients. Bortezomib,doxorubicin,and dexamethasone (PAD) is commonly used in clinical practice.Recent studies have found that…
- Trial name
- NCT02362165
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Croup
Croup Dosing Study
Croup is a common childhood respiratory disease that often leads to frequent emergency department visits. It is a viral infection that causes cough, throat, and airway swelling, making breathing difficult.
- Trial name
- NCT06272383
- Testing
- 0.15 mg/kg dexamethasone
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Leukemia
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute…
- Trial name
- NCT01009931
- Testing
- 12-O-tetradecanoylphorbol-13-acetate, Dexamethasone, Choline magnesium trisalicylate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Smoldering Plasma Cell Myeloma
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients.
- Trial name
- NCT04776395
- Testing
- Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Emory University
Multiple Myeloma
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
In the Netherlands, the standard treatment for multiple myeloma is a combination of different medicines named daratumumab-lenalidomide-dexamethasone, abbreviated as Dara-Rd.
- Trial name
- HOVON174MM (NCT06187441)
- Testing
- Daratumumab Injection, Dexamethasone, Lenalidomide capsule
- Where
- 38 sites in Netherlands
- Volunteers
- 599 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Multiple Myeloma
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently…
- Trial name
- OPTIMUM (NCT00452569)
- Testing
- Thalidomide, Dexamethasone
- Where
- 86 sites in Bulgaria, Croatia and 13 more
- Volunteers
- 499 people
- Sponsor
- Celgene